Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Janet Rader to Ovarian Neoplasms

This is a "connection" page, showing publications Janet Rader has written about Ovarian Neoplasms.

 
Connection Strength
  
 
 
2.908
  
  1. Kizer N, Zighelboim I, Rader JS. Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer. Int J Gynecol Cancer. 2009 Feb; 19(2):237-8.
    View in: PubMed
    Score: 0.243
  2. Li J, Olson LM, Zhang Z, Li L, Bidder M, Nguyen L, Pfeifer J, Rader JS. Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer. Int J Med Sci. 2008 Jun 06; 5(3):133-42.
    View in: PubMed
    Score: 0.232
  3. Moh M, Puzyrenko A, Summey R, Rader JS, Herrera Cano GE, Gavina JV, Rui H, Sun Y, Hopp E. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. Int J Gynecol Pathol. 2024 Sep 01; 43(5):527-534.
    View in: PubMed
    Score: 0.174
  4. Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol. 2003 Nov; 91(2):318-25.
    View in: PubMed
    Score: 0.169
  5. Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, Hart L, Chu Q, Oza A, Tinker AV, Imedio ER, Kumar S, Mugundu G, Jenkins S, Chmielecki J, Jones S, Spigel D, Fu S. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Target Oncol. 2023 Jul; 18(4):517-530.
    View in: PubMed
    Score: 0.164
  6. George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P. RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Rep. 2021 11 02; 37(5):109934.
    View in: PubMed
    Score: 0.147
  7. Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. Cancer Res. 2021 10 15; 81(20):5336-5352.
    View in: PubMed
    Score: 0.145
  8. Swisher EM, Babb S, Whelan A, Mutch DG, Rader JS. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. J Reprod Med. 2001 Feb; 46(2):87-94.
    View in: PubMed
    Score: 0.140
  9. Basil JB, Rader JS. Management of women at risk for malignancy. Curr Opin Oncol. 2000 Sep; 12(5):508-13.
    View in: PubMed
    Score: 0.136
  10. Chen C, Gupta P, Parashar D, Nair GG, George J, Geethadevi A, Wang W, Tsaih SW, Bradley W, Ramchandran R, Rader JS, Chaluvally-Raghavan P, Pradeep S. ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. Oncogene. 2020 04; 39(14):2921-2933.
    View in: PubMed
    Score: 0.130
  11. Rader JS, Neuman RJ, Brady J, Babb S, Temple S, Kost E, Mutch DG, Herzog TJ. Cancer among first-degree relatives of probands with invasive and borderline ovarian cancer. Obstet Gynecol. 1998 Oct; 92(4 Pt 1):589-95.
    View in: PubMed
    Score: 0.119
  12. Liapis H, Adler LM, Wick MR, Rader JS. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol. 1997 Apr; 28(4):443-9.
    View in: PubMed
    Score: 0.107
  13. Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet Gynecol. 1992 Feb; 4(1):120-7.
    View in: PubMed
    Score: 0.075
  14. Zighelboim I, Kizer N, Taylor NP, Case AS, Gao F, Thaker PH, Rader JS, Massad LS, Mutch DG, Powell MA. "Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer. Gynecol Oncol. 2010 Mar; 116(3):370-3.
    View in: PubMed
    Score: 0.065
  15. Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2008 Dec; 111(3):467-73.
    View in: PubMed
    Score: 0.059
  16. Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2008 Nov-Dec; 18(6):1194-9.
    View in: PubMed
    Score: 0.057
  17. Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer. 2008 May-Jun; 18(3):400-6.
    View in: PubMed
    Score: 0.055
  18. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer. 2006 Jul 01; 107(1):83-9.
    View in: PubMed
    Score: 0.051
  19. Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006 Nov; 103(2):637-41.
    View in: PubMed
    Score: 0.051
  20. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct; 103(1):212-8.
    View in: PubMed
    Score: 0.050
  21. Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG, Herzog TJ. Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol. 2005 Nov; 99(2):261-6.
    View in: PubMed
    Score: 0.048
  22. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ. Relationship of ovarian neoplasms and body mass index. J Reprod Med. 2005 Aug; 50(8):595-602.
    View in: PubMed
    Score: 0.048
  23. Srokowski T, Pfeifer JD, Li J, Olson LM, Rader JS. Expression and localization of GRP75 in human epithelial tumors and normal tissues. Appl Immunohistochem Mol Morphol. 2004 Jun; 12(2):132-8.
    View in: PubMed
    Score: 0.044
  24. Summey RM, Gornstein E, Decker B, Dougherty KC, Rader JS, Hopp E. Landscape of potential germline pathogenic variants in select cancer susceptibility genes in patients with adult-type ovarian granulosa cell tumors. Cancer Med. 2024 Jun; 13(12):e7340.
    View in: PubMed
    Score: 0.044
  25. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ. Synchronous ovarian metastases at the time of laparotomy for colon cancer. Gynecol Oncol. 2004 Mar; 92(3):851-5.
    View in: PubMed
    Score: 0.043
  26. Wright JD, Powell MA, Rader JS, Pfeifer JD, Huettner PC, Merritt DF. Acute abdominal pain with a calcified pelvic mass. J Pediatr Adolesc Gynecol. 2003 Aug; 16(4):237-41.
    View in: PubMed
    Score: 0.042
  27. Alvi AJ, Hogg R, Rader JS, Kuo MJ, Maher ER, Latif F. Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer. Mol Pathol. 2002 Jun; 55(3):153-5.
    View in: PubMed
    Score: 0.038
  28. Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol. 2002 Jan; 99(1):11-7.
    View in: PubMed
    Score: 0.037
  29. Alvi AJ, Rader JS, Broggini M, Latif F, Maher ER. Microsatellite instability and mutational analysis of transforming growth factor beta receptor type II gene (TGFBR2) in sporadic ovarian cancer. Mol Pathol. 2001 Aug; 54(4):240-3.
    View in: PubMed
    Score: 0.036
  30. Fullwood P, Marchini S, Rader JS, Martinez A, Macartney D, Broggini M, Morelli C, Barbanti-Brodano G, Maher ER, Latif F. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res. 1999 Sep 15; 59(18):4662-7.
    View in: PubMed
    Score: 0.032
  31. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997 Sep; 66(3):480-6.
    View in: PubMed
    Score: 0.028
  32. Adler LM, Herzog TJ, Williams S, Rader JS, Mutch DG. Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. Cancer. 1994 Oct 01; 74(7):1891-8.
    View in: PubMed
    Score: 0.023
  33. Huang YW, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS, Uyar DS. Hypermethylation of miR-203 in endometrial carcinomas. Gynecol Oncol. 2014 May; 133(2):340-5.
    View in: PubMed
    Score: 0.022
  34. Eng KH, Wang S, Bradley WH, Rader JS, Kendziorski C. Pathway index models for construction of patient-specific risk profiles. Stat Med. 2013 Apr 30; 32(9):1524-35.
    View in: PubMed
    Score: 0.020
  35. Leake JF, Rader JS, Woodruff JD, Rosenshein NB. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol. 1991 Aug; 42(2):124-30.
    View in: PubMed
    Score: 0.018
  36. Cohn DE, Mutch DG, Rader JS, Farrell M, Awantang R, Herzog TJ. Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies. Gynecol Oncol. 2001 Dec; 83(3):533-6.
    View in: PubMed
    Score: 0.009
  37. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001 Mar 22; 20(12):1509-18.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.